Literature DB >> 18705695

Remodelling of human osteoarthritic cartilage by FGF-2, alone or combined with Sox9 via rAAV gene transfer.

Magali Cucchiarini1, Ernest F Terwilliger2, Dieter Kohn1, Henning Madry1.   

Abstract

Compensating for the loss of extracellular cartilage matrix, as well as counteracting the alterations of the chondrocyte phenotype in osteoarthritis are of key importance to develop effective therapeutic strategies against this disorder. In the present study, we analysed the benefits of applying a potent gene combination to remodel human osteoarthritic (OA) cartilage. We employed the promising recombinant adeno-associated virus (rAAV) vector to deliver the mitogenic fibroblast growth factor 2 (FGF-2) factor, alone or simultaneously with the transcription factor Sox9 as a key activator of matrix synthesis, to human normal and OA articular chondrocytes. We evaluated the effects of single (FGF-2) or combined (FGF-2/SOX9) transgene expression upon the regenerative activities of chondrocytes in three dimensional cultures in vitro and in cartilage explants in situ. Single overexpression of FGF-2 enhanced the survival and proliferation of both normal and OA chondrocytes, without stimulating the matrix synthetic processes in the increased pools of cells. The mitogenic properties of FGF-2 were maintained when SOX9 was co-overexpressed and concomitant with an increase in the production of proteoglycans and type-II collagen, suggesting that the transcription factor was capable of counterbalancing the effects of FGF-2 on matrix accumulation. Also important, expression of type-X collagen, a marker of hypertrophy strongly decreased following treatment by the candidate vectors. Most remarkably, the levels of activities achieved in co-treated human OA cartilage were similar to or higher than those observed in normal cartilage. The present findings show that combined expression of candidate factors in OA cartilage can re-establish key features of normal cartilage and prevent the pathological shift of metabolic homeostasis. These data provide further motivation to develop coupled gene transfer approaches via rAAV for the treatment of human OA.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18705695      PMCID: PMC6512355          DOI: 10.1111/j.1582-4934.2008.00474.x

Source DB:  PubMed          Journal:  J Cell Mol Med        ISSN: 1582-1838            Impact factor:   5.310


  29 in total

1.  Benefits of recombinant adeno-associated virus (rAAV)-mediated insulinlike growth factor I (IGF-I) overexpression for the long-term reconstruction of human osteoarthritic cartilage by modulation of the IGF-I axis.

Authors:  Anja Weimer; Henning Madry; Jagadeesh K Venkatesan; Gertrud Schmitt; Janina Frisch; Anna Wezel; Jochen Jung; Dieter Kohn; Ernest F Terwilliger; Stephen B Trippel; Magali Cucchiarini
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

2.  Determination of effective rAAV-mediated gene transfer conditions to support chondrogenic differentiation processes in human primary bone marrow aspirates.

Authors:  A Rey-Rico; J Frisch; J K Venkatesan; G Schmitt; H Madry; M Cucchiarini
Journal:  Gene Ther       Date:  2014-10-23       Impact factor: 5.250

Review 3.  Osteoarthritis pathogenesis: a review of molecular mechanisms.

Authors:  Bingjiang Xia; Jushi Zhang; Songfeng Hu; Hongting Jin; Peijian Tong
Journal:  Calcif Tissue Int       Date:  2014-10-14       Impact factor: 4.333

4.  Regulation of articular chondrocyte aggrecan and collagen gene expression by multiple growth factor gene transfer.

Authors:  Shuiliang Shi; Scott Mercer; George J Eckert; Stephen B Trippel
Journal:  J Orthop Res       Date:  2011-12-16       Impact factor: 3.494

Review 5.  Use of tissue engineering strategies to repair joint tissues in osteoarthritis: viral gene transfer approaches.

Authors:  Magali Cucchiarini; Henning Madry
Journal:  Curr Rheumatol Rep       Date:  2014-10       Impact factor: 4.592

Review 6.  Tissue-engineering strategies to repair joint tissue in osteoarthritis: nonviral gene-transfer approaches.

Authors:  Henning Madry; Magali Cucchiarini
Journal:  Curr Rheumatol Rep       Date:  2014-10       Impact factor: 4.592

7.  Direct rAAV SOX9 administration for durable articular cartilage repair with delayed terminal differentiation and hypertrophy in vivo.

Authors:  Magali Cucchiarini; Patrick Orth; Henning Madry
Journal:  J Mol Med (Berl)       Date:  2012-11-13       Impact factor: 4.599

8.  Loss of spatial organization and destruction of the pericellular matrix in early osteoarthritis in vivo and in a novel in vitro methodology.

Authors:  T Felka; M Rothdiener; S Bast; T Uynuk-Ool; S Zouhair; B G Ochs; P De Zwart; U Stoeckle; W K Aicher; M L Hart; T Shiozawa; A J Grodzinsky; K Schenke-Layland; J K Venkatesan; M Cucchiarini; H Madry; B Kurz; B Rolauffs
Journal:  Osteoarthritis Cartilage       Date:  2016-02-12       Impact factor: 6.576

9.  Chondrogenic Differentiation Processes in Human Bone Marrow Aspirates upon rAAV-Mediated Gene Transfer and Overexpression of the Insulin-Like Growth Factor I.

Authors:  Janina Frisch; Ana Rey-Rico; Jagadeesh Kumar Venkatesan; Gertrud Schmitt; Henning Madry; Magali Cucchiarini
Journal:  Tissue Eng Part A       Date:  2015-07-22       Impact factor: 3.845

Review 10.  Advances in combining gene therapy with cell and tissue engineering-based approaches to enhance healing of the meniscus.

Authors:  M Cucchiarini; A L McNulty; R L Mauck; L A Setton; F Guilak; H Madry
Journal:  Osteoarthritis Cartilage       Date:  2016-04-05       Impact factor: 6.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.